Intensity Therapeutics, Inc.
INTS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | -0.22 | 3.09 | -0.32 |
| FCF Yield | -62.18% | -6.13% | -7.02% | -8.74% |
| EV / EBITDA | -1.35 | -10.82 | -10.83 | -9.63 |
| Quality | ||||
| ROIC | -542.70% | -62.29% | 1,324.56% | -216.91% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.68 | 0.72 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -111.24% | -31.54% | 19.77% | -27.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | 0.83 | -0.42 | 0.28 |
| Interest Coverage | 0.00 | -27.28 | -92.32 | -477.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -7,568.16 | 0.00 | 0.00 |